What is JBIO's enterprise value?

JBIO (JBIO) reported enterprise value of $638.62M in Q1 2026.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

JBIO JBIO Enterprise value

Enterprise value at other companies

Vertex PharmaceuticalsVRTX

$109.92B-9.5%

Travere Therapeutics, Inc.TVTX

$2.68B+65.5%

Vera TherapeuticsVERA

$2.83B+85.0%

AnaptysBio, Inc.ANAB

$1.35B+176%

Cullinan Therapeutics, Inc.CGEM

$787.38M+114%

Viridian Therapeutics, Inc.VRDN

$1.86B+85.0%

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

$692.9Mmarket cap+$808.0Ktotal debt−$55.1Mcash and equivalents=$638.62M

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's enterprise value?: JBIO (JBIO) reported enterprise value of $638.62M in Q1 2026.
What does enterprise value mean?: Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.